SCHEMBL21597587

SCHEMBL21597587

CCOC(=O)C1CCCc2c1sc(N)c2C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.48
MAPT P10636 10/20 0.48
GAA P10253 9/20 0.48
HPGD P15428 8/20 0.48
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
KDM4E B2RXH2 5/20 0.48
POLB P06746 2/20 0.48
RECQL P46063 2/20 0.48
RXFP1 Q9HBX9 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HSD17B10 Q99714 4/20 0.47
ALOX15 P16050 2/20 0.47
MAPK1 P28482 1/20 0.47
TSHR P16473 1/20 0.46
ALOX12 P18054 1/20 0.46
ADORA1 P30542 3/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15241910 0.90 ALDH1A1 (0.60) ALDH1A1MAPTGAAHPGDMEN1
SCHEMBL21597739 0.81 MAPT (0.47) ALDH1A1MAPTGAAHPGDKMT2A
SCHEMBL15236766 0.80 ALDH1A1 (0.60) ALDH1A1MAPTGAAHPGDMEN1
SCHEMBL5837538 0.79 ADORA1 (0.44) ALDH1A1MAPTGAAHPGDMEN1
SCHEMBL21597537 0.78 ALDH1A1 (0.42) ALDH1A1MAPTGAAHPGDMEN1
SCHEMBL21597835 0.78 ALDH1A1 (0.50) ALDH1A1MAPTGAAHPGDMEN1
SCHEMBL21597821 0.76 ALDH1A1 (0.52) ALDH1A1MAPTGAAHPGDMEN1
SCHEMBL3496757 0.76 ALDH1A1 (0.61) ALDH1A1MAPTGAAHPGDMEN1
SCHEMBL21597781 0.75 ALDH1A1 (0.61) ALDH1A1MAPTGAAHPGDMEN1
SCHEMBL5837061 0.72 ADORA1 (0.52) ALDH1A1MAPTGAAHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 ALDH1A1 233/4885MAPT 2356/4885GAA 724/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 ALDH1A1 233/4885MAPT 2356/4885GAA 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.